Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $39.00 Average PT from Analysts

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are currently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $39.00.

A number of research firms have issued reports on COLL. Needham & Company LLC reiterated a “buy” rating and set a $40.00 target price on shares of Collegium Pharmaceutical in a report on Thursday, April 11th. Jefferies Financial Group reiterated a “hold” rating and issued a $37.00 target price (up from $30.00) on shares of Collegium Pharmaceutical in a report on Thursday, January 4th. StockNews.com downgraded Collegium Pharmaceutical from a “strong-buy” rating to a “buy” rating in a report on Friday, March 29th. Piper Sandler reiterated an “overweight” rating and issued a $39.00 price objective (up previously from $37.00) on shares of Collegium Pharmaceutical in a research note on Friday, February 23rd. Finally, Truist Financial upped their target price on shares of Collegium Pharmaceutical from $37.00 to $40.00 and gave the stock a “buy” rating in a research note on Monday, February 26th.

Collegium Pharmaceutical Trading Up 0.1 %

COLL opened at $35.45 on Friday. Collegium Pharmaceutical has a 52 week low of $20.83 and a 52 week high of $40.95. The company has a quick ratio of 1.10, a current ratio of 1.17 and a debt-to-equity ratio of 2.48. The business has a fifty day simple moving average of $36.82 and a 200-day simple moving average of $30.72. The firm has a market cap of $1.16 billion, a P/E ratio of 30.04 and a beta of 1.03.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its earnings results on Thursday, February 22nd. The specialty pharmaceutical company reported $1.45 EPS for the quarter, beating analysts’ consensus estimates of $1.20 by $0.25. The company had revenue of $149.75 million during the quarter, compared to analysts’ expectations of $147.66 million. Collegium Pharmaceutical had a return on equity of 107.39% and a net margin of 8.50%. On average, equities analysts expect that Collegium Pharmaceutical will post 5.63 earnings per share for the current year.

Hedge Funds Weigh In On Collegium Pharmaceutical

Hedge funds have recently added to or reduced their stakes in the stock. SummerHaven Investment Management LLC increased its position in shares of Collegium Pharmaceutical by 1.1% during the fourth quarter. SummerHaven Investment Management LLC now owns 34,034 shares of the specialty pharmaceutical company’s stock worth $1,048,000 after purchasing an additional 368 shares in the last quarter. Illinois Municipal Retirement Fund boosted its position in shares of Collegium Pharmaceutical by 2.1% in the 4th quarter. Illinois Municipal Retirement Fund now owns 19,879 shares of the specialty pharmaceutical company’s stock valued at $612,000 after purchasing an additional 411 shares during the period. West Tower Group LLC grew its stake in Collegium Pharmaceutical by 101.8% during the 4th quarter. West Tower Group LLC now owns 892 shares of the specialty pharmaceutical company’s stock worth $27,000 after buying an additional 450 shares during the last quarter. Maverick Capital Ltd. increased its position in Collegium Pharmaceutical by 5.2% during the first quarter. Maverick Capital Ltd. now owns 11,296 shares of the specialty pharmaceutical company’s stock worth $271,000 after buying an additional 555 shares during the period. Finally, Los Angeles Capital Management LLC lifted its stake in Collegium Pharmaceutical by 0.8% in the third quarter. Los Angeles Capital Management LLC now owns 76,876 shares of the specialty pharmaceutical company’s stock valued at $1,718,000 after buying an additional 585 shares during the last quarter.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.